Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, has announced the successful completion of the European Union Good Manufacturing Practice (EU GMP) inspection conducted by the Federal Agency for Medicines and Health Products, Belgium (FAMHP).

The inspection was carried out at the company's manufacturing facility from 24th November 2025 to 28th November 2025. The audit was completed with zero critical and zero major observations, reflecting the company's strong quality systems, robust manufacturing infrastructure, and strict adherence to global regulatory standards.

Commenting on the development, the management said: "Successfully completing the EU GMP inspection by the FAMHP, Belgium with zero critical and zero major observations is a testament to our teams' dedication to quality and compliance. This achievement enhances our ability to serve regulated markets and supports our long-term strategic growth objectives."

Bharat Parenterals and Innoxel Lifesciences remain commiƩed to expanding their global footprint through continued investments in quality, systems, and regulatory excellence.